Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation ...

In Evaluate’s recently released annual World Preview Report, including updated global pharmaceutical market projections ...

The Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Angelini has fallen short of its standards by ...

Novo Nordisk has just released the topline findings from two eagerly anticipated phase 3 trials of its oral formulation of ...

Whilst the NHS indubitably runs on international talent, however, this does not stop our system from pushing overseas nurses ...

The positive result in OCEANIC-STROKE means that asundexian can potentially now sit alongside prostate cancer therapy Nubeqa ...

J&J is also running mid-stage trials of a tau active immunotherapy codenamed JNJ-2056 for Alzheimer's, while other active tau ...

Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group of companies ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in bipolar ...

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas. Under the terms ...

UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a pivotal ...

Randall Bateman, MD, Charles F and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove ...